Last updated on May 2018

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

Brief description of study

Primary Objective:

To demonstrate equivalence of Gan & Lee Insulin Glargine Injection and Lantus in terms of immunogenicity

Secondary Objective:

Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26

Clinical Study Identifier: NCT03371108

Find a site near you

Start Over

Meridien Research

Bradenton, FL United States
  Connect »